Printer Friendly

The US FDA approves Cimzia for the treatment for patients with nr-axSpA.

Global Banking News-March 29, 2019-The US FDA approves Cimzia for the treatment for patients with nr-axSpA

(C)2019 ENPublishing -

Public health agency The US Food and Drug Administration Thursday authorised Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA).

According to the company, Nr-axSpA is a type of inflammatory arthritis that causes inflammation in the spine and other symptoms. There is no visible damage seen on x-rays, so it is referred to as non-radiographic.

The agency has granted the approval of Cimzia to UCB.

As there has been no US FDA-approved treatments until now, this is the first time the agency has approved a treatment for nr-axSpA, with objective signs of inflammation.

In conjunction, the efficacy of Cimzia for the treatment of nr-axSpA was studied in the company's randomized clinical trial in 317 adult patients with nr-axSpA with objective signs of inflammation, indicated by elevated C-reactive protein (CRP) levels and/or sacroiliitis (inflammation of the sacroiliac joints) on MRI. The trial measured the improvement response on the Ankylosing Spondylitis Disease Activity Score, a composite scoring system. Responses were greater for patients treated with Cimzia compared to patients treated with placebo. The overall safety profile observed in the Cimzia treatment group was consistent with the known safety profile of Cimzia.

((Distributed via M2 Communications -

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Global Banking News (GBN)
Date:Mar 29, 2019
Previous Article:DNA reports on 2019 AGM.
Next Article:Luye Pharma expects Rykindo to be the first Chinese drug to receive US FDA approval.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters